Masashi Kato1, Akihiro Hirakawa2, Yumiko Kobayashi3, Akiyuki Yamamoto4, Ryo Ishida5, Tomoyasu Sano6, Tohru Kimura7, Tsuyoshi Majima1, Shohei Ishida1, Yasuhito Funahashi1, Naoto Sassa1, Takashi Fujita1, Yoshihisa Matsukawa1, Tokunori Yamamoto1, Ryohei Hattori8, Momokazu Gotoh1, Toyonori Tsuzuki9. 1. Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 2. Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 3. Statistical Analysis Section, Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan. 4. Department of Urology, Toyohashi Municipal Hospital, Toyohashi, Japan. 5. Department of Urology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan. 6. Department of Urology, Komaki City Hospital, Komaki, Japan. 7. Department of Urology, JCHO Chukyo Hospital, Nagoya, Japan. 8. Department of Urology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan. 9. Department of Surgical Pathology, Aichi Medical University, School of Medicine, Nagakute, Japan.
Abstract
BACKGROUND: Although the presence of intraductal carcinoma of the prostate (IDC-P) influences biochemical failure in radical prostatectomy patients, no data are available regarding the impact of its integration into the classification grade group system. Thus, the aim of this study was to enhance the utility of the grade group system by integrating the presence of IDC-P. METHODS: This study was a retrospective evaluation of 1019 patients with prostate cancer who underwent radical prostatectomy between 2005 and 2013 without neoadjuvant or adjuvant therapy. The data on age, prostate-specific antigen (PSA) level at diagnosis, pathological T stage (pT), presence of Gleason pattern 5 (GP5), presence of IDC-P, and surgical margin status were analyzed to predict PSA recurrence after prostatectomy. RESULTS: The median patient age was 67 (range, 45-80) years and the median initial PSA level was 6.8 (range, 0.4-82) ng/mL. The median follow-up period was 82 (range, 0.7-148) months. IDC-P was detected in 157 patients (15.4%). Among these patients, the increase in the positive rate of IDC-P correlated with tumor upgrading. The grade groups (GGs) were as follows: GG1 without IDC-P, 16.0% (n = 163); GG2 without IDC-P, 46.1% (n = 470); GG3 without IDC-P, 15.7% (n = 160); GG4 without IDC-P, 2.6% (n = 27); GG5 without IDC-P, 4.1% (n = 42); any GG with IDC-P, 15.4% [n = 157; GG 2 (n = 29); GG3 (n = 60); GG4 (n = 13); GG5 (n = 55)]. Any grade Group with IDC-P showed significantly worse prognosis than any other group without IDC-P (P < 0.0001). In a multivariate analysis, integration of the IDC-P into the Grade Groups, the PSA level at diagnosis, and the surgical margin status were significant prognostic predictors (P < 0.0001, < 0.0001 and < 0.0001, respectively). CONCLUSIONS: Integrating the presence of IDC-P into the grade group system will result in more accurate predictions of patient outcome.
BACKGROUND: Although the presence of intraductal carcinoma of the prostate (IDC-P) influences biochemical failure in radical prostatectomy patients, no data are available regarding the impact of its integration into the classification grade group system. Thus, the aim of this study was to enhance the utility of the grade group system by integrating the presence of IDC-P. METHODS: This study was a retrospective evaluation of 1019 patients with prostate cancer who underwent radical prostatectomy between 2005 and 2013 without neoadjuvant or adjuvant therapy. The data on age, prostate-specific antigen (PSA) level at diagnosis, pathological T stage (pT), presence of Gleason pattern 5 (GP5), presence of IDC-P, and surgical margin status were analyzed to predict PSA recurrence after prostatectomy. RESULTS: The median patient age was 67 (range, 45-80) years and the median initial PSA level was 6.8 (range, 0.4-82) ng/mL. The median follow-up period was 82 (range, 0.7-148) months. IDC-P was detected in 157 patients (15.4%). Among these patients, the increase in the positive rate of IDC-P correlated with tumor upgrading. The grade groups (GGs) were as follows: GG1 without IDC-P, 16.0% (n = 163); GG2 without IDC-P, 46.1% (n = 470); GG3 without IDC-P, 15.7% (n = 160); GG4 without IDC-P, 2.6% (n = 27); GG5 without IDC-P, 4.1% (n = 42); any GG with IDC-P, 15.4% [n = 157; GG 2 (n = 29); GG3 (n = 60); GG4 (n = 13); GG5 (n = 55)]. Any grade Group with IDC-P showed significantly worse prognosis than any other group without IDC-P (P < 0.0001). In a multivariate analysis, integration of the IDC-P into the Grade Groups, the PSA level at diagnosis, and the surgical margin status were significant prognostic predictors (P < 0.0001, < 0.0001 and < 0.0001, respectively). CONCLUSIONS: Integrating the presence of IDC-P into the grade group system will result in more accurate predictions of patient outcome.
Authors: Emily Chan; Jesse K McKenney; Sarah Hawley; Dillon Corrigan; Heidi Auman; Lisa F Newcomb; Hilary D Boyer; Peter R Carroll; Matthew R Cooperberg; Eric Klein; Ladan Fazli; Martin E Gleave; Antonio Hurtado-Coll; Jeffry P Simko; Peter S Nelson; Ian M Thompson; Maria S Tretiakova; Dean Troyer; Lawrence D True; Funda Vakar-Lopez; Daniel W Lin; James D Brooks; Ziding Feng; Jane K Nguyen Journal: Mod Pathol Date: 2022-02-10 Impact factor: 8.209
Authors: James G Kench; Mahul B Amin; Daniel M Berney; Eva M Compérat; Ian A Cree; Anthony J Gill; Arndt Hartmann; Santosh Menon; Holger Moch; George J Netto; Maria R Raspollini; Mark A Rubin; Puay Hoon Tan; Toyonori Tsuzuki; Samra Turjalic; Theo H van der Kwast; Ming Zhou; John R Srigley Journal: Histopathology Date: 2022-08-02 Impact factor: 7.778